Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 84

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 84
---
     |              39,000 |     |      2,562,040 |
| Brett Pletcher             |     |                    — |     |              — |     |                   — |     |              — |
| Ching W. Jaw               |     |              197,812 |     |      8,483,206 |     |              25,000 |     |      1,682,400 |

| (1) | The amounts shown in this column represent the number of shares of Common Stock acquired on exercise multiplied by the excess of the closing price of a Cytokinetics share on the date of exercise over the option exercise price. |

| (2) | Equal to the closing trading price of our Common Stock on the day of vesting multiplied by the number of shares released on vesting. |

Executive Employment and Other Agreements We have (or had, as applicable) executive employment agreements with each named executive officer that provide (or provided, as applicable) for such officers to remain at-will employees and to receive salary, non-equity incentive plan payments and benefits as determined at the discretion of the Board of Directors and for such officers to receive certain benefits if, upon or within the eighteen-month period following a change of control of the Company, they resign for good reason or are terminated by us or our successor other than for cause and sign a standard release of claims with us. See “Potential Payments Upon Termination or Change of Control” below.

| Cytokinetics, Inc.|2025 Proxy Statement |     | 59 |

TABLE OF CONTENTS EXECUTIVE COMPENSATION Pension Benefits We do not provide our employees, including our named executive officers, with a defined benefit pension plan or any supplemental executive retirement plans or retiree health benefits. Nonqualified Deferred Compensation We do not have a nonqualified defined contribution plan or other nonqualified deferred compensation plan. Potential Payments Upon Termination or Change of Control We have (or had, as applicable) executive employment agreements with each named executive officer that provide (or provided, as applicable) for such officers to remain at-will employees and to receive salary, non-equity incentive plan payments and benefits as determined at the discretion of the Board of Directors and provide for such officers to receive certain benefits if, upon or within the eighteen-month period following a change of control of the Company, they resign for good reason or are terminated by us or our successor other than for cause (a “qualifying resignation or termination”) and such officer signs a standard release of